NeoGenomics, Inc. (NEO) — Fair Value Analysis

Base-case fair value (P50): $20.23 · Current price: $15.94 · Verdict: Undervalued

The Verdict on NEO

Our Monte Carlo simulations indicate that NEOGENOMICS INC (NEO) is currently Fairly Valued. With NEO trading at $15.94, our median fair value (P50) stands at $20.23. This suggests an potential upside of +26.9% based on our current assessment, positioning the company neither as significantly undervalued nor overvalued at present. This "Fairly Valued" verdict is derived from thousands of forward-looking scenarios, providing a probabilistic view of its intrinsic value.

How NEO stacks up against peers

NEO's operational and financial health is currently assessed as "average" within its sector. This quality tier suggests that while the company is performing adequately, it does not stand out significantly above or below its peers in terms of fundamental strength. An average quality tier, coupled with a median fair value of $20.23 against a current price of $15.94, implies that NEO is priced largely in line with its fundamental characteristics and market expectations for a company of its standing. The implied +26.9% reflects the normalized expectation given its current profile.

What this means for investors

For investors considering NEOGENOMICS INC, the "Fairly Valued" verdict and "average" quality tier suggest a balanced risk-reward profile at the current $15.94. While there's a modeled upside of +26.9% to our P50 fair value of $20.23, this is not indicative of deep undervaluation. Instead, it points to a reasonable valuation given the company's fundamentals. Investors seeking substantial discrepancies may look for tickers with greater divergences from their P50. To see the full bear (P10) and bull (P90) distribution for NEO and track its fair value as new fundamentals are released, sign up for a free FairCurve account.